A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Coherent Biopharma (Hefei) Co., Ltd.
Beijing Friendship Hospital
NGM Biopharmaceuticals, Inc
European Institute of Oncology
Centre Hospitalier Universitaire Vaudois
Universitair Ziekenhuis Brussel
SpotitEarly
Central South University
University Hospital, Ghent
Massachusetts General Hospital
Lebanese University
Fondazione per la Medicina Personalizzata
Massachusetts General Hospital
Kineta Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shanghai Yunying Medical Technology
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Shanghai Yunying Medical Technology
Université Sorbonne Paris Nord
Chongqing Precision Biotech Co., Ltd
Assistance Publique - Hôpitaux de Paris
University of Kansas Medical Center
Jules Bordet Institute
Provectus Pharmaceuticals
Second Affiliated Hospital of Soochow University
Blue Note Therapeutics
Imperial College London
Silverback Therapeutics
Assistance Publique - Hôpitaux de Paris
Weprom
Shanghai Fengxian District Central Hospital
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
SpeciCare
MetiMedi Pharmaceuticals
Institut Paoli-Calmettes
Sun Yat-sen University
Petra Pharma
The First Affiliated Hospital of Dalian Medical University
Samyang Biopharmaceuticals Corporation
The First Affiliated Hospital of Dalian Medical University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
National Taiwan University Hospital
Peking Union Medical College
Royal Marsden NHS Foundation Trust
M.D. Anderson Cancer Center
KU Leuven
Xuanwu Hospital, Beijing
Quantgene Inc.
Biological Dynamics
Centre Hospitalier Universitaire de Besancon